Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Selecta Biosciences Inc. maintains a presence in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions currently active. These actions are distributed across 3 distinct examiners, indicating a diverse range of perspectives within the USPTO. This distribution requires the applicant to manage multiple prosecution tracks simultaneously.
The portfolio is further spread across 3 distinct art units. This variety suggests that the underlying technologies may span different specialized niches within the broader biotechnology field. HUYNH, PHUONG N is identified as the busiest examiner for the company, currently responsible for 1 busiest examiner pending action.
With 3 pending office actions and 3 distinct examiners, each matter is being handled by a different individual. The presence of 3 distinct art units means that the prosecution strategy must be tailored to the specific requirements of different administrative groups. Since the busiest examiner pending count is 1, the workload is distributed among the assigned examiners, with no 1 individual managing all pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.9% | +53.6% |
| CURRENS, GRANT CARSON | 1 | 54.5% | +60.4% |
| LIU, TRACY | 1 | 54.3% | +26.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17092148 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CURRENS, GRANT CARSON | 26d |
| 18177714 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS | HUYNH, PHUONG N | — |
| 14934132 | METHODS AND COMPOSITIONS RELATED TO THE USE OF LOW HLB SURFACTANTS IN THE PRODUCTION OF SYNTHETIC NANOCARRIERS COMPRISING A RAPALOG | LIU, TRACY | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1651 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18177714 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS | HUYNH, PHUONG N | 1641 | DP | Final Rejection | — | Pending | Mar 02, 2023 |
| 17092148 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CURRENS, GRANT CARSON | 1651 | §103Other | Final Rejection | 26d | Pending | Nov 06, 2020 |
| 14934132 | METHODS AND COMPOSITIONS RELATED TO THE USE OF LOW HLB SURFACTANTS IN THE PRODUCTION OF SYNTHETIC NANOCARRIERS COMPRISING A RAPALOG | LIU, TRACY | 1614 | §103DP | Non-Final OA | — | Pending | Nov 05, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSelecta Biosciences Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Phuong N Huynh has the most, with 1 of Selecta Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.